GH Research Announces FDA Lifts Clinical Hold on GH001, Clearing Path for Global Phase 3 Initiation in 2026
GH Research PLC - Ordinary Shares (GHRS)
Company Research
Source: GlobeNewswire
GH001 cleared by FDA for U.S. clinical investigation, enabling U.S. subject enrollmentCompany to seek FDA alignment on global Phase 3 program replicating Phase 2b designPhase 3 initiation targeted for 2026 DUBLIN, Jan. 05, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its Investigational New Drug Application (IND) for GH001. This clearance enables U.S. subject enrollment and progresses the company toward alignment of its development across major jurisdictions. “The FDA clearance is a major milestone and positions us to advance GH001 as a potential ultra-rapid and durable treatment option for TRD patients,” said Dr. Velichka Valcheva, Chief Executive Officer. “We continue to expect initiation of our global pivotal program in 20
Show less
Read more
Impact Snapshot
Event Time:
GHRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GHRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GHRS alerts
High impacting GH Research PLC - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GHRS
News
- GH Research (NASDAQ:GHRS) was given a new $29.00 price target on by analysts at Needham & Company LLC.MarketBeat
- GH Research (NASDAQ:GHRS) was given a new $39.00 price target on by analysts at Wolfe Research.MarketBeat
- GH Research (NASDAQ:GHRS) was given a new $39.00 price target on by analysts at Canaccord Genuity Group Inc..MarketBeat
- GH Research (NASDAQ:GHRS) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- GH Research (NASDAQ:GHRS) had its "buy" rating reaffirmed by analysts at Cowen Inc.MarketBeat
GHRS
Earnings
- 5/8/25 - Beat
GHRS
Sec Filings
- 1/15/26 - Form 6-K
- 1/13/26 - Form 6-K
- 1/8/26 - Form 6-K
- GHRS's page on the SEC website